IL310937A - COMPOSITIONS CONTAINING NON-SERIAL MIXTURES OF (R) AND (S)-3,4-METHYLENEDIOXYMETHAMPHETAMINE OR (R) AND (S) N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE AND THEIR USES - Google Patents
COMPOSITIONS CONTAINING NON-SERIAL MIXTURES OF (R) AND (S)-3,4-METHYLENEDIOXYMETHAMPHETAMINE OR (R) AND (S) N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE AND THEIR USESInfo
- Publication number
- IL310937A IL310937A IL310937A IL31093724A IL310937A IL 310937 A IL310937 A IL 310937A IL 310937 A IL310937 A IL 310937A IL 31093724 A IL31093724 A IL 31093724A IL 310937 A IL310937 A IL 310937A
- Authority
- IL
- Israel
- Prior art keywords
- solvate
- salt
- mdma
- disorder
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163235460P | 2021-08-20 | 2021-08-20 | |
| US202263298820P | 2022-01-12 | 2022-01-12 | |
| PCT/CA2022/051269 WO2023019369A1 (en) | 2021-08-20 | 2022-08-22 | Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310937A true IL310937A (en) | 2024-04-01 |
Family
ID=85239329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310937A IL310937A (en) | 2021-08-20 | 2022-08-22 | COMPOSITIONS CONTAINING NON-SERIAL MIXTURES OF (R) AND (S)-3,4-METHYLENEDIOXYMETHAMPHETAMINE OR (R) AND (S) N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE AND THEIR USES |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US12053452B2 (https=) |
| EP (1) | EP4387612A4 (https=) |
| JP (1) | JP2024531437A (https=) |
| KR (1) | KR20240061644A (https=) |
| AU (1) | AU2022330718B2 (https=) |
| CA (1) | CA3229363A1 (https=) |
| IL (1) | IL310937A (https=) |
| WO (1) | WO2023019369A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022283967A1 (en) * | 2021-06-03 | 2024-01-18 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
| KR20240165982A (ko) * | 2022-03-31 | 2024-11-25 | 트랜센드 테라퓨틱스 인코퍼레이티드 | 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022150525A1 (en) * | 2021-01-06 | 2022-07-14 | Awakn Life Sciences | Mdma in the treatment of alcohol use disorder |
| WO2022235500A1 (en) | 2021-05-03 | 2022-11-10 | Mind Medicine, Inc. | Psychedelics for treatment of pain |
| JP2024517194A (ja) | 2021-05-03 | 2024-04-19 | マインド メディシン， インコーポレイテッド | サイケデリック薬の用量を漸増する方法 |
| US12611399B2 (en) | 2021-05-04 | 2026-04-28 | Definium Therapeutics US, Inc. | Movement disorders |
| WO2022235514A1 (en) | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Liposome delivery of psychedelics |
| US20220354822A1 (en) * | 2021-05-05 | 2022-11-10 | Mind Medicine, Inc. | Mdma enantiomers |
| WO2022232948A1 (en) * | 2021-05-06 | 2022-11-10 | Pharmala Biotech Inc. | Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb) |
| WO2022232949A1 (en) * | 2021-05-06 | 2022-11-10 | Pharmala Biotech Inc. | Processes for the preparation of the enantiomers of 3,4-methylenedioxymethamphetamine (mdma) and n-methyl-1,3-benzodioxolylbutanamine (mbdb) |
| AU2022283967A1 (en) | 2021-06-03 | 2024-01-18 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
| WO2023056472A1 (en) | 2021-09-30 | 2023-04-06 | ATAI Life Sciences AG | Enantiomeric ratios of 3,4-methylenedioxymethamphetamine and related metabolites and uses thereof |
| CA3242786A1 (en) | 2022-01-07 | 2023-07-13 | Universitatsspital Basel | R-mdma and s-mdma to assist psychotherapy |
-
2022
- 2022-08-22 AU AU2022330718A patent/AU2022330718B2/en active Active
- 2022-08-22 JP JP2024510674A patent/JP2024531437A/ja active Pending
- 2022-08-22 EP EP22857191.5A patent/EP4387612A4/en active Pending
- 2022-08-22 IL IL310937A patent/IL310937A/en unknown
- 2022-08-22 CA CA3229363A patent/CA3229363A1/en active Pending
- 2022-08-22 WO PCT/CA2022/051269 patent/WO2023019369A1/en not_active Ceased
- 2022-08-22 KR KR1020247009362A patent/KR20240061644A/ko active Pending
-
2023
- 2023-03-06 US US18/117,723 patent/US12053452B2/en active Active
-
2024
- 2024-06-19 US US18/747,519 patent/US20240335419A1/en active Pending
-
2025
- 2025-01-29 US US19/040,188 patent/US20250170095A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022330718B2 (en) | 2026-02-19 |
| US12053452B2 (en) | 2024-08-06 |
| EP4387612A1 (en) | 2024-06-26 |
| WO2023019369A1 (en) | 2023-02-23 |
| AU2022330718A1 (en) | 2024-03-28 |
| CA3229363A1 (en) | 2023-02-23 |
| JP2024531437A (ja) | 2024-08-29 |
| US20250170095A1 (en) | 2025-05-29 |
| EP4387612A4 (en) | 2025-07-23 |
| KR20240061644A (ko) | 2024-05-08 |
| US20230201159A1 (en) | 2023-06-29 |
| US20240335419A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL310937A (en) | COMPOSITIONS CONTAINING NON-SERIAL MIXTURES OF (R) AND (S)-3,4-METHYLENEDIOXYMETHAMPHETAMINE OR (R) AND (S) N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE AND THEIR USES | |
| US20240100039A1 (en) | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation | |
| CN115811975A (zh) | 增强lsd、赛洛西宾或其他致幻剂的急性情绪效应特征的mdma治疗 | |
| IL297251A (en) | lsd dose detection | |
| JP2007510753A (ja) | ゴーシェ病を治療するための、グルコイミダゾール誘導体およびポリヒドロキシシクロヘキセニルアミン誘導体 | |
| JP2025502054A (ja) | 精神療法を支援するためのｒ－ｍｄｍａ及びｓ－ｍｄｍａ | |
| IL297642A (en) | Methods for using t-type calcium channel modulators | |
| IL275289B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| TW202532057A (zh) | 用於治療或預防神經系統病症及其症狀及表現、以及用於對抗疾病及細胞老化及其症狀及表現之細胞保護之化合物 | |
| IL322319A (en) | Treatment of mental illness by administering bontanatep and its analogues | |
| IL319372A (en) | Combinations involving psychedelic drugs for the treatment of chronic schizophrenia and other neuropsychiatric and neurological disorders | |
| CN118176000A (zh) | 包含(r)-和(s)-3,4-亚甲基二氧基甲基苯丙胺或者(r)和(s)n-甲基-1,3-苯并间二氧杂环戊烯基丁胺的非外消旋混合物的组合物及其用途 | |
| HK40107764A (zh) | 包含(r)-和(s)-3，4-亚甲基二氧基甲基苯丙胺或者(r)和(s)n-甲基-1，3-苯并间二氧杂环戊烯基丁胺的非外消旋混合物的组合物及其用途 | |
| IL317451A (en) | (R)-2-[(2H-1,3-BENZODIOXOL-5-YL)METHYL]PYRROLIDINE, METHODS FOR PREPARATION, COMPOUNDS, AND USES THEREOF | |
| IL321950A (en) | Preparations and methods for controlling glucose levels | |
| HK40029163A (en) | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation | |
| HK1228453A1 (en) | Compositions for treatment of disorders ameliorated by muscarinic receptor activation | |
| HK1228453B (en) | Compositions for treatment of disorders ameliorated by muscarinic receptor activation |